were both subpoenaed by the New York attorney general as part of an investigation of the drug industry's secondary market.
Both firms said they were cooperating with the probe. AmerisourceBergen also noted that its purchases from other drug wholesalers make up just 0.5% of its overall drug buying, and said such wholesalers are subject to background checks and other quality controls.
"AmerisourceBergen has been working closely with many manufacturers to minimize the need for pharmaceutical purchases from alternate sources," the company said. "AmerisourceBergen purchases from alternate sources to maintain high service levels to customers when products are in short supply and in some cases to improve its margin."
The company said it's unaware of any allegations of wrongdoing.
, Cardinal and Amerisource dominate the business of selling drugs to large buyers like hospitals and pharmacies. The sector has been repeatedly torpedoed over the last year by squeezed profit margins and inventory issues, most recently at Amerisource, which cut its full-year profit forecast from between $4 and $4.10 a share to between $3.10 and $3.50 a share last week.